|
1
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar :
|
|
3
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ying SY, Chang DC, Miller JD and Lin SL:
The microRNA: Overview of the RNA gene that modulates gene
functions. Methods Mol Biol. 342:1–18. 2006.PubMed/NCBI
|
|
5
|
Maroney PA, Yu Y and Nilsen TW: MicroRNAs,
mRNAs, and translation. Cold Spring Harb Symp Quant Biol.
71:531–535. 2006. View Article : Google Scholar
|
|
6
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McManus MT: MicroRNAs and cancer. Semin
Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amirkhah R, Schmitz U, Linnebacher M,
Wolkenhauer O and Farazmand A: MicroRNA-mRNA interactions in
colorectal cancer and their role in tumor progression. Genes
Chromosomes Cancer. 54:129–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong Y, Yu J and Ng SS: MicroRNA
dysregulation as a prognostic biomarker in colorectal cancer.
Cancer Manag Res. 6:405–422. 2014.PubMed/NCBI
|
|
12
|
Tokarz P and Blasiak J: The role of
microRNA in metastatic colorectal cancer and its significance in
cancer prognosis and treatment. Acta Biochim Pol. 59:467–474.
2012.PubMed/NCBI
|
|
13
|
Zhang X, Tang J, Zhi X, Xie K, Wang W, Li
Z, Zhu Y, Yang L, Xu H and Xu Z: miR-874 functions as a tumor
suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway
in gastric cancer. Oncotarget. 6:1605–1617. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang B, Li Z, Zhang W, Wang H, Zhi X,
Feng J, Chen Z, Zhu Y, Yang L, Xu H, et al: miR-874 Inhibits cell
proliferation, migration and invasion through targeting aquaporin-3
in gastric cancer. J Gastroenterol. 49:1011–1025. 2014. View Article : Google Scholar
|
|
15
|
Wang L, Gao W, Hu F, Xu Z and Wang F:
MicroRNA-874 inhibits cell proliferation and induces apoptosis in
human breast cancer by targeting CDK9. FEBS Lett. 588:4527–4535.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kesanakurti D, Maddirela DR, Chittivelu S,
Rao JS and Chetty C: Suppression of tumor cell invasiveness and in
vivo tumor growth by microRNA-874 in non-small cell lung cancer.
Biochem Biophys Res Commun. 434:627–633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nohata N, Hanazawa T, Kikkawa N, Sakurai
D, Fujimura L, Chiyomaru T, Kawakami K, Yoshino H, Enokida H,
Nakagawa M, et al: Tumour suppressive microRNA-874 regulates novel
cancer networks in maxillary sinus squamous cell carcinoma. Br J
Cancer. 105:833–841. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qu Y, Xia P, Zhang S, Pan S and Zhao J:
Silencing XIAP suppresses osteosarcoma cell growth, and enhances
the sensitivity of osteosarcoma cells to doxorubicin and cisplatin.
Oncol Rep. 33:1177–1184. 2015.PubMed/NCBI
|
|
19
|
Sheng L, He P, Yang X, Zhou M and Feng Q:
miR-612 negatively regulates colorectal cancer growth and
metastasis by targeting AKT2. Cell Death Dis. 6:e18082015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Z, Liu S, Tian L, Wu M, Ai F, Tang W,
Zhao L, Ding J, Zhang L and Tang A: miR-124 and miR-506 inhibit
colorectal cancer progression by targeting DNMT3B and DNMT1.
Oncotarget. 6:38139–38150. 2015.PubMed/NCBI
|
|
21
|
Ren XL, He GY, Li XM, Men H, Yi LZ, Lu GF,
Xin SN, Wu PX, Li YL, Liao WT, et al: MicroRNA-206 functions as a
tumor suppressor in colorectal cancer by targeting FMNL2. J Cancer
Res Clin Oncol. Oct 29–2015.Epub ahead of print. PubMed/NCBI
|
|
22
|
Nohata N, Hanazawa T, Kinoshita T, Inamine
A, Kikkawa N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Okamoto
Y, et al: Tumour-suppressive microRNA-874 contributes to cell
proliferation through targeting of histone deacetylase 1 in head
and neck squamous cell carcinoma. Br J Cancer. 108:1648–1658. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Salvesen GS and Duckett CS: IAP proteins:
Blocking the road to death's door. Nat Rev Mol Cell Biol.
3:401–410. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiang G, Wen X, Wang H, Chen K and Liu H:
Expression of X-linked inhibitor of apoptosis protein in human
colorectal cancer and its correlation with prognosis. J Surg Oncol.
100:708–712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Connolly K, Mitter R, Muir M, Jodrell D
and Guichard S: Stable XIAP knockdown clones of HCT116 colon cancer
cells are more sensitive to TRAIL, taxanes and irradiation in
vitro. Cancer Chemother Pharmacol. 64:307–316. 2009. View Article : Google Scholar
|
|
26
|
Yamaguchi Y, Shiraki K, Fuke H, Inoue T,
Miyashita K, Yamanaka Y, Saitou Y, Sugimoto K and Nakano T:
Targeting of X-linked inhibitor of apoptosis protein or survivin by
short interfering RNAs sensitize hepatoma cells to TNF-related
apoptosis-inducing ligand- and chemotherapeutic agent-induced cell
death. Oncol Rep. 14:1311–1316. 2005.PubMed/NCBI
|
|
27
|
Jiang C, Yi XP, Shen H and Li YX:
Targeting X-linked inhibitor of apoptosis protein inhibits
pancreatic cancer cell growth through p-Akt depletion. World J
Gastroenterol. 18:2956–2965. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Heidelberger C, Chaudhuri NK, Danneberg P,
Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E and
Scheiner J: Fluorinated pyrimidines, a new class of
tumour-inhibitory compounds. Nature. 179:663–666. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Longley DB, Allen WL and Johnston PG: Drug
resistance, predictive markers and pharmacogenomics in colorectal
cancer. Biochim Biophys Acta. 1766:184–196. 2006.PubMed/NCBI
|
|
31
|
Zhang Y, Talmon G and Wang J: MicroRNA-587
antagonizes 5-FU-induced apoptosis and confers drug resistance by
regulating PPP2R1B expression in colorectal cancer. Cell Death Dis.
6:e18452015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim SA, Kim I, Yoon SK, Lee EK and Kuh HJ:
Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96
in human colorectal cancer cells. Arch Pharm Res. 38:239–248. 2015.
View Article : Google Scholar
|
|
33
|
Zhao HJ, Ren LL, Wang ZH, Sun TT, Yu YN,
Wang YC, Yan TT, Zou W, He J, Zhang Y, et al: MiR-194 deregulation
contributes to colorectal carcinogenesis via targeting AKT2
pathway. Theranostics. 4:1193–1208. 2014. View Article : Google Scholar : PubMed/NCBI
|
